Safheal · Product development ·
Safheal introduces its Aβ42 Rapid Test for professional biomarker assessment
Safheal has announced a newly developed amyloid beta 42 (Aβ42) rapid test. It provides a qualitative indication of an elevated Aβ42 signal in human serum or EDTA plasma as an aid to professional assessment.
The assay uses a colloidal gold sandwich format with a procedural control line. Its technical documentation distinguishes specimen eligibility from the result the cassette can report, helping laboratories assess where it could fit in their existing evaluation pathway.
Aβ42 is a biomarker associated with amyloid pathology research. This single-marker assay neither reports a concentration or ratio nor establishes brain amyloid pathology. It cannot diagnose or exclude Alzheimer’s disease on its own; interpret findings with clinical history and other appropriate examinations.